48-week results) 2 JAMA Network (2023)Retatrutide Phase 2 Obesity Trial: detailed efficacy and safety data (24% weight loss at 12 mg weekly) 3 The Lancet (2023)Retatrutide in type 2 diabetes: Phase 2 trial (weight loss and glycemic outcomes at 36 weeks) 4 PubMed / NEJM (2023)Retatrutide dosing and tolerability: starting at 2 mg vs 4 mg reduces GI adverse events 5 Metabolites (PMC, 2025)RetatrutideA Game Changer in Obesity Pharmacotherapy (comprehensive review of mechanism and trials) 6 Baylor University Medical Center Proceedings (PMC, 2025)Efficacy and safety of retatrutide for obesity: meta-analysis of RCTs (878 participants) 7 PubMed (2025)Meta-analysis: Retatrutide achieves ~14% greater weight reduction vs placebo with no increase in adverse events 8 Molecular Metabolism (2025)Preclinical tri-agonist NN1706 (related compound): mechanism and pharmacokinetics 9 Nature Reviews Endocrinology (2024)Triple agonist therapies for obesity and diabetes: clinical landscape review 10 Journal of Cachexia, Sarcopenia and Muscle (PMC)Protein requirements during weight loss: preserving lean mass 11 GenScriptPeptide Storage and Handling Guidelines (technical bulletin for lyophilized and reconstituted peptides) 12 BachemHandling and Storage Guidelines for Peptides (technical article on stability and freeze-thaw cycles) 13 Centers for Disease Control and Prevention (CDC)Vaccine Administration: Subcutaneous Injection (technique, angle, and site guidance) 14 NCBI BookshelfInjection Administration Best Practices (aseptic technique, sharps disposal, and safety) 15 Pharmacologic Considerations of the Subcutaneous Route (PMC)Subcutaneous injection technique and site rotation to prevent lipohypertrophy 16 Prime Lab PeptidesRetatrutide (6 mg) product page (quality documentation and specifications) Retatrutide frequently asked questions How do I reconstitute a 10 mg vial of Retatrutide
(eds.) Proceedings of the Thirteenth Language Resources and Evaluation Conference, LREC 2022, Marseille, France, 20-25 June 2022 , 71847190 (European Language Resources Association, 2022)
[Accessed: 29.01.2012]
This article does not constitute medical advice
The rest are add-ons
TXNIP, a novel key factor to cause Schwann cell dysfunction in diabetic peripheral neuropathy, under the regulation of PI3K/Akt pathway inhibition-induced DNMT1 and DNMT3a overexpression
